Evidence map›Paper›PMID 34831154›Full record

ArticleCells2021

Evaluation of Immunomodulatory Responses and Changed Wound Healing in Type 2 Diabetes-A Study Exploiting Dermal Fibroblasts from Diabetic and Non-Diabetic Human Donors.

Kimberly Nickel, Ursula Wensorra, Horst Wenck, Nils Peters, Harald Genth

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. miR‑222‑3p inhibits diabetic skin wound healing by targeting APLN.International journal of molecular medicine · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Accelerated Wound Healing in Diabetic Rat by miRNA-185-5p and Its Anti-Inflammatory Activity.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kimberly NickelResearch Department, Beiersdorf AG, D-20245 Hamburg, Germany.ORCID 0000-0002-0476-4329
Ursula WensorraResearch Department, Beiersdorf AG, D-20245 Hamburg, Germany.
Horst WenckResearch Department, Beiersdorf AG, D-20245 Hamburg, Germany.
Nils PetersResearch Department, Beiersdorf AG, D-20245 Hamburg, Germany.
Harald GenthInstitute of Toxicology, Hanover Medical School, D-30623 Hanover, Germany.
Beiersdorf (Germany) · DEMedizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The dermis is the connective layer between the epidermis and subcutis and harbours nerve endings, glands, blood vessels, and hair follicles. The most abundant cell type is the fibroblast. Dermal fibroblasts have a versatile portfolio of functions within the dermis that correspond with different types of cells by either direct contact or by autocrine and paracrine signalling. Diabetic skin is characterized by itching, numbness, ulcers, eczema, and other pathophysiological changes. These pathogenic phenotypes have been associated with the effects of the reactive glucose metabolite methylglyoxal (MGO) on dermal cells. In this study, dermal fibroblasts were isolated from diabetic and non-diabetic human donors. Cultured dermal fibroblasts from diabetic donors exhibited reduced insulin-induced glucose uptake and reduced expression of the insulin receptor. This diabetic phenotype persists under cell culture conditions. Secretion of IL-6 was increased in fibroblasts from diabetic donors. Increased secretion of IL-6 and MIF was also observed upon the treatment of dermal fibroblasts with MGO, suggesting that MGO is sufficient for triggering these immunomodulatory responses. Remarkably, MIF treatment resulted in decreased activity of MGO-detoxifying glyoxalase-1. Given that reduced glyoxalase activity results in increased MGO levels, these findings suggested a positive-feedback loop for MGO generation, in which MIF, evoked by MGO, in turn blocks MGO-degrading glyoxalase activity. Finally, secretion of procollagen Type I C-Peptide (PICP), a marker of collagen production, was reduced in fibroblast from diabetic donors. Remarkably, treatment of fibroblasts with either MGO or MIF was sufficient for inducing reduced PICP levels. The observations of this study unravel a signalling network in human dermal fibroblasts with the metabolite MGO being sufficient for inflammation and delayed wound healing, hallmarks of T2D.

Indexed as

ImmunomodulationTissue DonorsDermisDiabetes Mellitus, Type 2FemaleFibroblastsGlucoseHumansInsulinInterleukin-6Lactoylglutathione LyaseMacrophage Migration-Inhibitory FactorsMaleMiddle AgedPeptide FragmentsProcollagenGlucoseInsulinInterleukin-6Lactoylglutathione LyaseMacrophage Migration-Inhibitory FactorsPeptide FragmentsProcollagenprocollagen type I carboxy terminal peptidePyruvaldehydeReceptor, Insulindiabetesglyoxalase IMIFskin

Identifiers

PMID34831154
PMCPMC8616411
OpenAlexW3209539904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.